Long-term management and persistent impairment of pulmonary function in chronic eosinophilic pneumonia: A review of the previous literature
Author(s) -
Yuzo Suzuki,
Takafumi Suda
Publication year - 2018
Publication title -
allergology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.49
H-Index - 58
eISSN - 1440-1592
pISSN - 1323-8930
DOI - 10.1016/j.alit.2017.12.004
Subject(s) - medicine , etiology , pneumonia , asthma , disease , pulmonary function testing , eosinophilic , eosinophilic pneumonia , pulmonary eosinophilia , intensive care medicine , respiratory disease , immunology , pediatrics , lung , eosinophil , pathology
Chronic eosinophilic pneumonia (CEP) is an inflammatory disease characterized by accumulations of eosinophils in the lung with unknown etiology. Although corticosteroid treatment dramatically resolves these inflammations, relapse is common during the course of the disease. Approximately 50% of patients with CEP experience relapse. Subsequent to persistent disease and repeated relapse, and in cases of combined severe asthma, some CEP patients are administered corticosteroids indefinitely. Similar to patients with severe asthma who are often steroid dependent, a number of CEP patients exhibit prolonged persistent impairment of pulmonary function. Thus, CEP should be considered a potentially chronic disease requiring long-term management, rather than an acute or sub-acute disease requiring short-time therapy only. This review summarizes previous CEP studies, as well as our own cohort data, and discusses the long-term management of CEP with a particular focus on relapse, the prevalence of maintenance therapy, and persistent impairment of pulmonary function.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom